 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...891011121314151617181920» |
- || Sovaldi (sofosbuvir) / Gilead, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Vosevi Works Well as #HepatitisC Salvage Treatment by @benryanwriter https://t.co/62jRRWboA8 @GileadSciences #EASL2019 #Epclusa #Harvoni #salvagetherapy #Sovaldi #Vosevi (Twitter) - Apr 15, 2019
- Co-administration of directly antiviral agents for HCV and second line MDR-TB drugs: a multi-centre French case series (HALL C) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_3506;
In this small group of patients, no significant adverse events or drug interactions were observed. DAAs should be considered in patients with HCV co-infection receiving MDR-TB treatment, to increase its tolerability and avoid treatment interruption.
- paritaprevir/ritonavir (ABT-450/r) / AbbVie
The comparison of hepatitis C treatment outcomes with direct acting antivirals between people who inject drugs (PWID) and non-PWID: results from a national survey in Slovenia () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1144;
Our results confirm excellent SVR rates of DAAs in real-life setting with better results achieved in non-PWID compared to PWID. However, excluding those with premature treatment discontinuation for unknown reasons and the lack of FU12, the SVR rates were comparable between the two groups.
- Copegus (ribavirin) / Bausch Health, sofosbuvir/velpatasvir / Generic mfg.
Chronic and acute HEV infection: an Italian experience () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1035;
Even though our data suggest that the circulation of HEV-RNA in the healthy population is absent, seeming to be detectable only in ill-patients, as an emerging cause of acute and chronic hepatitis with potential severe complications in immunosuppressed patients. Therefore, HEV-infection should be considered as a differential diagnosis of unexplained deranged liver function tests.
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment change: Expanding the Pool in Orthotopic Heart Transplantation (clinicaltrials.gov) - Mar 28, 2019
P2, N=20, Recruiting, Sponsor: University of Pittsburgh
Therefore, HEV-infection should be considered as a differential diagnosis of unexplained deranged liver function tests. N=100 --> 20
- | sofosbuvir/velpatasvir / Generic mfg.
New P3 trial: Micro-elimination of Hepatitis C Virus Infection in Uremics (clinicaltrials.gov) - Mar 27, 2019
P3, N=135, Recruiting, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Enrollment open: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant (clinicaltrials.gov) - Mar 7, 2019
P4, N=25, Recruiting, Sponsor: Massachusetts General Hospital
N=100 --> 20 Not yet recruiting --> Recruiting
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Phase classification, Trial initiation date: TEMPO: A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (clinicaltrials.gov) - Feb 28, 2019
P=N/A, N=300, Not yet recruiting, Sponsor: Kirby Institute
Not yet recruiting --> Recruiting Phase classification: P4 --> P=N/A | Initiation date: Nov 2018 --> Apr 2019
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: Transplanting Hepatitis C Positive Organs (clinicaltrials.gov) - Feb 12, 2019
P4, N=100, Recruiting, Sponsor: Brigham and Women's Hospital
Phase classification: P4 --> P=N/A | Initiation date: Nov 2018 --> Apr 2019 N=32 --> 100 | Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Mar 2018 --> Dec 2020
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment open: SHELTER: Transplanting Hepatitis C Lungs Into Negative Lung Recipients (clinicaltrials.gov) - Feb 7, 2019
P1/2, N=10, Recruiting, Sponsor: University of Pennsylvania
N=32 --> 100 | Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Mar 2018 --> Dec 2020 Not yet recruiting --> Recruiting
- || sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: HepNet acute HCV-V: Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir (clinicaltrials.gov) - Jan 28, 2019
P2, N=20, Not yet recruiting, Sponsor: Hannover Medical School
- | sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients (clinicaltrials.gov) - Jan 28, 2019
P2, N=20, Not yet recruiting, Sponsor: Naudia Jonassaint
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: CRUSADE-1: Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (clinicaltrials.gov) - Jan 23, 2019
P4, N=14, Recruiting, Sponsor: Radboud University
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- | sofosbuvir/velpatasvir / Generic mfg.
New P2 trial: The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients (clinicaltrials.gov) - Jan 18, 2019
P2, N=60, Not yet recruiting, Sponsor: Amit Tevar
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
New P2/3 trial: USE-Hep C: Utilization of Hepatitis C Positive Kidneys in Negative Recipients (clinicaltrials.gov) - Jan 11, 2019
P2/3, N=25, Recruiting, Sponsor: Ohio State University
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (clinicaltrials.gov) - Jan 10, 2019
P4, N=75, Recruiting, Sponsor: Elizabeth Krans, MD
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Dec 2019 --> Feb 2021 | Trial primary completion date: Dec 2018 --> Feb 2020
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial completion: Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis (clinicaltrials.gov) - Dec 21, 2018
P2, N=32, Completed, Sponsor: Gilead Sciences
Trial completion date: Dec 2019 --> Feb 2021 | Trial primary completion date: Dec 2018 --> Feb 2020 Active, not recruiting --> Completed
- || sofosbuvir/velpatasvir / Generic mfg.
Trial initiation date: HCV Post-Exposure Prophylaxis for Health Care Workers (clinicaltrials.gov) - Dec 20, 2018
P4, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Initiation date: Aug 2018 --> Mar 2019
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Trial initiation date: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant (clinicaltrials.gov) - Dec 20, 2018
P4, N=25, Not yet recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Aug 2018 --> Mar 2019 Initiation date: Oct 2018 --> Jan 2019
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
New trial: SCALE-C: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (clinicaltrials.gov) - Dec 17, 2018
P, N=600, Not yet recruiting, Sponsor: Kirby Institute
- || sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed, Adherence: DASH: Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (clinicaltrials.gov) - Dec 13, 2018
P=N/A, N=253, Active, not recruiting, Sponsor: Proteus Digital Health, Inc.
Initiation date: Oct 2018 --> Jan 2019 Recruiting --> Active, not recruiting
- ||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: GS-US-342-4062: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Dec 11, 2018
P2, N=59, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | sofosbuvir/velpatasvir / Generic mfg.
Trial initiation date: Expanding the Pool in Lung Transplantation (clinicaltrials.gov) - Dec 5, 2018
P1, N=100, Not yet recruiting, Sponsor: Jonathan D'Cunha
Active, not recruiting --> Completed Initiation date: Oct 2018 --> Apr 2019
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment closed: Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients (clinicaltrials.gov) - Nov 28, 2018
P1, N=25, Active, not recruiting, Sponsor: Virginia Commonwealth University
Initiation date: Oct 2018 --> Apr 2019 Recruiting --> Active, not recruiting
- | sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion date, Trial primary completion date: BArT: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection (clinicaltrials.gov) - Nov 20, 2018
P2, N=44, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Recruiting --> Active, not recruiting Trial completion date: Oct 2020 --> May 2022 | Trial primary completion date: Oct 2018 --> May 2019
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD)
New P1/2 trial: SHELTER: Transplanting Hepatitis C Lungs Into Negative Lung Recipients (clinicaltrials.gov) - Oct 29, 2018
P1/2, N=10, Not yet recruiting, Sponsor: University of Pennsylvania
- | ribavirin / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: MINMON: Monitoring SOF/VEL in Treatment Na (clinicaltrials.gov) - Oct 18, 2018
P4, N=400, Recruiting, Sponsor: AIDS Clinical Trials Group
Trial completion date: Oct 2020 --> May 2022 | Trial primary completion date: Oct 2018 --> May 2019 Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial (clinicaltrials.gov) - Oct 11, 2018
P4, N=7, Completed, Sponsor: Ala'a Sharara
Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022 Recruiting --> Completed | N=10 --> 7 | Trial completion date: Sep 2017 --> Aug 2018 | Trial primary completion date: Aug 2017 --> Aug 2018
- | sofosbuvir/velpatasvir / Generic mfg.
New P1 trial: Hepatitis C Positive Donor Into Hepatitis C Negative Recipients (clinicaltrials.gov) - Oct 11, 2018
P1, N=50, Not yet recruiting, Sponsor: University of Maryland
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Trial completion date, Trial initiation date, Trial primary completion date: TEMPO: A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (clinicaltrials.gov) - Sep 21, 2018
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
Recruiting --> Completed | N=10 --> 7 | Trial completion date: Sep 2017 --> Aug 2018 | Trial primary completion date: Aug 2017 --> Aug 2018 Trial completion date: Jul 2019 --> Nov 2019 | Initiation date: Jul 2018 --> Nov 2018 | Trial primary completion date: Jul 2019 --> Nov 2019
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date, Adherence: DASH: Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (clinicaltrials.gov) - Sep 17, 2018
P=N/A, N=253, Recruiting, Sponsor: Proteus Digital Health, Inc.
Trial completion date: Jul 2019 --> Nov 2019 | Initiation date: Jul 2018 --> Nov 2018 | Trial primary completion date: Jul 2019 --> Nov 2019 Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed, Combination therapy: Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) (clinicaltrials.gov) - Sep 12, 2018
P2a, N=12, Active, not recruiting, Sponsor: Cocrystal Pharma, Inc.
Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Apr 2019 Recruiting --> Active, not recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic (clinicaltrials.gov) - Sep 7, 2018
P4, N=20, Recruiting, Sponsor: Community Research Initiative of New England
Recruiting --> Active, not recruiting Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Aug 2018 --> Aug 2019
- | sofosbuvir/velpatasvir / Generic mfg.
Trial initiation date: Expanding the Pool in Lung Transplantation (clinicaltrials.gov) - Aug 17, 2018
P1, N=100, Not yet recruiting, Sponsor: Jonathan D'Cunha
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Aug 2018 --> Aug 2019 Initiation date: Feb 2018 --> Oct 2018
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: HCV Seek, Test and Rapid Treatment for Young PWID (clinicaltrials.gov) - Aug 13, 2018
P4, N=72, Recruiting, Sponsor: Weill Medical College of Cornell University
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
New P4 trial: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant (clinicaltrials.gov) - Aug 9, 2018
P4, N=25, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Combination therapy: Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) (clinicaltrials.gov) - Jul 18, 2018
P2a, N=12, Recruiting, Sponsor: Cocrystal Pharma, Inc.
Initiation date: Feb 2018 --> Oct 2018 Not yet recruiting --> Recruiting
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P4 trial: Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy (clinicaltrials.gov) - Jul 15, 2018
P4, N=25, Recruiting, Sponsor: Saskatchewan Health Authority - Regina Area
- | Sovaldi (sofosbuvir) / Gilead
Journal: Rational Heart Transplant From Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan. (Pubmed Central) - Jul 12, 2018
The feasibility of early versus late treatment of HCV remains to be determined through formalized protocols. We hypothesize pharmacoeconomics to be the greatest limitation to widespread availability of this promising tool.
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment open, Enrollment change: Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients (clinicaltrials.gov) - Jun 6, 2018
P1, N=25, Recruiting, Sponsor: Virginia Commonwealth University
We hypothesize pharmacoeconomics to be the greatest limitation to widespread availability of this promising tool. Active, not recruiting --> Recruiting | N=10 --> 25
- | sofosbuvir/velpatasvir / Generic mfg.
New trial: People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (clinicaltrials.gov) - May 13, 2018
P=N/A, N=450, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- | ribavirin / Generic mfg.
New P4 trial: MINMON: Monitoring SOF/VEL in Treatment Na (clinicaltrials.gov) - Apr 30, 2018
P4, N=400, Not yet recruiting, Sponsor: AIDS Clinical Trials Group
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: GS-US-342-1518: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV (clinicaltrials.gov) - Apr 27, 2018
P3, N=375, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Recruiting | N=10 --> 25 Active, not recruiting --> Completed
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment closed: Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients (clinicaltrials.gov) - Apr 26, 2018
P1, N=10, Active, not recruiting, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial. (Pubmed Central) - Apr 24, 2018
Recruiting --> Active, not recruiting This placebo-controlled trial shows that patients treated with SOF/VEL experience significant improvement of their PROs during treatment and after achieving SVR.
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Journal: Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C. (Pubmed Central) - Apr 24, 2018
Patients with prior DAA treatment failure, genotype 3, cirrhosis and/or unfavorable resistance profiles all achieved cure rates of 96% or greater. The most distinctive role for this potent regimen may prove to be as a salvage regimen for patients who have failed previous DAA therapy.
- | ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed, Enrollment change: Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis (clinicaltrials.gov) - Apr 23, 2018
P2, N=32, Active, not recruiting, Sponsor: Gilead Sciences
The most distinctive role for this potent regimen may prove to be as a salvage regimen for patients who have failed previous DAA therapy. Recruiting --> Active, not recruiting | N=50 --> 32
- | sofosbuvir/velpatasvir / Generic mfg.
New P2a trial, Combination therapy: Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) (clinicaltrials.gov) - Apr 17, 2018
P2a, N=12, Not yet recruiting, Sponsor: Cocrystal Pharma, Inc.
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: CRUSADE-1: Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (clinicaltrials.gov) - Apr 12, 2018
P4, N=14, Recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting | N=50 --> 32 Not yet recruiting --> Recruiting
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia (clinicaltrials.gov) - Apr 10, 2018
P2/3, N=10, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Not yet recruiting --> Recruiting Trial completion date: Feb 2018 --> Dec 2018 | Trial primary completion date: Feb 2018 --> Dec 2018